Effects of Erythropoietin-Stimulating Agents on Blood Pressure in Patients with Non-Dialysis CKD and Renal Anemia

• Príomhchruthaitheoirí: Kohji Ohki (Údar), Hiromichi Wakui (Údar), Kazushi Uneda (Údar), Kengo Azushima (Údar), Kotaro Haruhara (Údar), Sho Kinguchi (Údar), Shingo Urate (Údar), Takayuki Yamada (Údar), Takahiro Yamaji (Údar), Ryu Kobayashi (Údar), Tomohiko Kanaoka (Údar), Shintaro Minegishi (Údar), Tomoaki Ishigami (Údar), Tetsuya Fujikawa (Údar), Yoshiyuki Toya (Údar), Kouichi Tamura (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: Karger Publishers, 2020-06-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

Introduction: Erythropoietin-stimulating agents (ESAs) are used to treat renal anemia in patients with non-dialysis CKD, but this can lead to increases in blood pressure (BP). Objective: We investigated the effects of continuous erythropoietin receptor activator (CERA) and darbepoetin alfa (DA) on o...